Concepedia

Author

Christopher Bruno

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

C Bruno, C. Bruno, Christopher Bruno, Christopher J Bruno, Christopher J. Bruno

55

Publications

784

Citations

15

H-Index

21

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Washington University in St. LouisNorthwestern UniversitySt. James's HospitalUniversitat de Barcelona
CB

About

Christopher Bruno is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

453

2

Humanities

1

1

17

3

Public Health

1

1

17

4

Health Policy

1

1

17

5

Immunology

1

1

41

Christopher Bruno

×

17

Publications

704

Citations

15

H-Index

YearCitations

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial

Marin H. Kollef, Martin Nováček, Ülo Kivistik,

The Lancet Infectious Diseases

2019

329

Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

Jean‐François Timsit, Jennifer A. Huntington, Richard G. Wunderink,

Critical Care

2021

46

Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial

Andreas H. Groll, Hisham Abdel‐Azim, Thomas Lehrnbecher,

International Journal of Antimicrobial Agents

2020

43

Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial

Heather Platt, Christopher Bruno, Erik Buntinx,

The Lancet Infectious Diseases

2024

41

The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients

Valerianna Amorosa, Jihad Slim, Karam Mounzer,

Antiviral Therapy

2010

27

Safety and Efficacy of Ceftolozane/Tazobactam Versus Meropenem in Neonates and Children With Complicated Urinary Tract Infection, Including Pyelonephritis: A Phase 2, Randomized Clinical Trial

Emmanuel Roilides, Negar Ashouri, John S. Bradley,

The Pediatric Infectious Disease Journal

2023

25

Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia

Zufei Zhang, Yogesh T. Patel, Jill Fiedler‐Kelly,

The Journal of Clinical Pharmacology

2020

23

Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial

David L. Paterson, Matteo Bassetti, Mary Motyl,

Journal of Antimicrobial Chemotherapy

2022

21

Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

Andrew F. Shorr, Christopher Bruno, Zufei Zhang,

Critical Care

2021

20

Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia

Ignacio Martín‐Loeches, Jean‐François Timsit, Marin H. Kollef,

Journal of Antimicrobial Chemotherapy

2021

20

Page 1